@article{ea91875bf5b044509f86933ae8e840ae,
title = "Are all licensed haemostatic agents for haemophilia therapy accessible to patients?",
author = "\{the International Prophylaxis Study Group\} and Karin Berger and Angelika Batorova and Rhonda Bohn and \{di Minno\}, Matteo and Mannucci, \{Pier Mannuccio\} and Kaan Kavakli and Wolfgang Schramm and Louis Aledort",
note = "Funding Information: The authors of this letter to the editor are members of the Access Expert Working Group of the International Prophylaxis Study Group (the IPSG). The opinions stated in this letter to the editor are those of the named authors and as well reflect input from the members of the IPSG Executive (Drs. Victor Blanchette, Louis Aledort and Rolf Ljung). The International Prophylaxis Study Group (IPSG), is a not‐for‐profit organisation funded by educational grants to the Hospital for Sick Children (“SickKids”) Foundation from Bayer, Novo Nordisk Health Care AG, Pfizer, Sanofi, Takeda and Spark Therapeutics. None of the industry sponsors of the IPSG, nor a commercial medical writing service were involved with the preparation of this letter to the editor. ",
year = "2022",
month = nov,
doi = "10.1111/hae.14660",
language = "English",
volume = "28",
pages = "e256--e258",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "John Wiley and Sons Inc.",
number = "6",
}